Analyst Consensus ?
ConsensusHold13 ratings
Bullish538.5%
Neutral753.8%
Bearish17.7%
Viatris Inc. · VTRS · FY2026 Q1 · Calendar Q2 2026
Viatris Beats Q1 Estimates as Greater China Surges 18% and Pipeline Advances
Viatris posted a Q1 beat with revenue of $3.52B and EPS of $0.59, driven by 18% YoY growth in Greater China and new product contributions. The pipeline advanced with EFFEXOR's Japan approval and progress toward FDA decisions on XULANE LO and fast-acting meloxicam. Management reaffirmed 2026 guidance and emphasized disciplined capital allocation with $2.5B in cash. The stock initially surged 9.3% before drifting back roughly 8.7%, suggesting investors are weighing whether China momentum and pipeline execution are sustainable against policy and supply risks.
Reported Before market openNASDAQHealthcare
$20.68B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.59
Consensus $0.50
EPS surprise
+17.5%
Reported versus consensus
Reported revenue
$3.52B
Consensus $3.36B
Revenue surprise
+4.8%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+9.0%
Event window
SPY move
-0.3%
Same window
Abnormal move
+9.3%
Stock minus SPY
Volume
3.2×
Versus trailing sessions
Subsequent drift
-8.7%
Up to 20 sessions
VTRSSPY benchmark
Ask FN2 about VTRS FY2026 Q1
Transcript, numbers and history already loaded
Why did VTRS rise 9.0% after beating EPS estimates in FY2026 Q1?What changed in VTRS's guidance and outlook in FY2026 Q1?Give me the bull and bear case for VTRS after FY2026 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Revenue of $3.52B beat consensus by 4.8% and EPS of $0.59 exceeded estimates by 17.5%. Greater China grew 18% YoY with e-commerce sales doubling, while new products including Creon and iron sucrose contributed $71M in revenue. The stock rose 9.3% on the report at 3.2x normal volume but subsequently drifted back approximately 8.7%.
Guidance delta
Management maintained full-year 2026 guidance, consistent with the prior quarter. The cost-savings program targeting $120M in 2026 remains on track. Capital allocation priorities -- dividends, share repurchases, and selective in-market acquisitions -- are unchanged, supported by $2.5B in cash.
Key takeaways
- Q1 revenue of $3.52B and adjusted EBITDA of approximately $1.0B both beat consensus, with Greater China growing 18% YoY.
- EFFEXOR received approval in Japan for generalized anxiety disorder; FDA decisions for XULANE LO and fast-acting meloxicam are pending.
- E-commerce sales in Greater China doubled year-over-year, signaling accelerating commercial execution.
- Cost-saving initiatives targeting $120M in 2026 remain on track, supporting EBITDA margin expansion.
- Management reaffirmed 2026 guidance with $2.5B in cash available for dividends, buybacks, and strategic investments.
Management priorities
- Launch XULANE LO in the US by July 2026
- Seek FDA approval and launch fast-acting meloxicam by year-end 2026
- Commercialize EFFEXOR and pitolisant in Japan and pursue additional indications
- Deliver pipeline readouts for Nefecon, selatogrel, and cenerimod in 2026-2027
- Continue cost-saving initiatives targeting $120M in 2026
- Deploy cash through dividends, share repurchases, and selective in-market acquisitions
Follow VTRS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$18.77Previous close
$12Low
$18.64Average
$26High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Neutral | Neutral | Maintain | Oct 26, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Oct 21, 2026 |
| UBS | Buy | Buy | Maintain | Oct 5, 2026 |
| Argus Research | Buy | Buy | Maintain | Sep 8, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | May 8, 2026 |
| Jefferies | Buy | Buy | Maintain | Mar 7, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Feb 28, 2025 |
| BMO Capital | Market Perform | Outperform | Downgrade | Feb 17, 2023 |
| Goldman Sachs | Neutral | Neutral | Maintain | May 12, 2022 |
| Citigroup | Neutral | Neutral | Maintain | Mar 10, 2022 |
| Raymond James | Market Perform | Outperform | Downgrade | Mar 1, 2022 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Mar 10, 2021 |
Named analyst price targets
Upside is calculated against the persisted previous close $18.77. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | David Amsellem | $14 | $18 | -25.4% | Oct 26, 2026 |
| UBS | Ashwani Verma | $26 | $17.6 | +38.5% | Oct 5, 2026 |
| Oppenheimer | Analyst unavailable | $25 | $17.18 | +33.2% | Sep 23, 2026 |
| Leerink Partners | Analyst unavailable | $20 | $16.61 | +6.6% | Sep 9, 2026 |
| Argus Research | Analyst unavailable | $20 | $16.75 | +6.6% | Sep 8, 2026 |
| Barclays | Glen Santangelo | $22 | $16.5 | +17.2% | May 19, 2026 |
| Truist Financial | Analyst unavailable | $20 | $16.94 | +6.6% | May 8, 2026 |
| UBS | Ashwani Verma | $18 | $14.58 | -4.1% | Feb 9, 2026 |
| Piper Sandler | Analyst unavailable | $12 | $13.12 | -36.1% | Jan 28, 2026 |
| Argus Research | Analyst unavailable | $15 | $12.84 | -20.1% | Jan 16, 2026 |
| Truist Financial | Les Sulewski | $16 | $12.4 | -14.8% | Jan 7, 2026 |
| Truist Financial | Analyst unavailable | $15 | $9.93 | -20.1% | Oct 15, 2025 |
| Jefferies | Glen Santangelo | $15 | $11.77 | -20.1% | Jul 19, 2024 |
| Piper Sandler | David Amsellem | $13 | $11.83 | -30.7% | Mar 28, 2024 |
| Piper Sandler | David Amsellem | $10 | $9.84 | -46.7% | Jun 26, 2023 |
| Barclays | Analyst unavailable | $15 | $12.16 | -20.1% | Feb 1, 2023 |
| UBS | Ashwani Verma | $12 | $10.83 | -36.1% | Nov 9, 2022 |
| UBS | Ashwani Verma | $9 | $10.77 | -52.1% | Jun 13, 2022 |
Track every rating change on VTRS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationViatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors.…
Historical context
All VTRS earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BIIB Biogen Inc. | FY2026 Q3 · Calendar Q4 2026 | +31.7% | -3.4% | Biogen’s Q3 growth broadened beyond legacy MS franchise |
| GSK GSK plc | FY2026 Q3 · Calendar Q4 2026 | +10.5% | -4.3% | GSK Q3 2026: Specialty Medicines Drive Growth as Guidance Holds |
| BSX Boston Scientific Corporation | FY2026 Q3 · Calendar Q4 2026 | +2.0% | -5.8% | Boston Scientific: Cyber Incident Weighs on Q3; 2027 Outlook Softens |
| AVTR Avantor, Inc. | FY2026 Q3 · Calendar Q4 2026 | +5.3% | -2.6% | Avantor reports stronger growth and raises 2026 outlook |
| ENSG The Ensign Group, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +8.6% | Ensign raises earnings outlook as acquisitions and occupancy support growth |
| GEHC GE HealthCare Technologies Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +6.6% | GE HealthCare raises 2026 outlook as margins expand |
Latest beats and misses
Who reports nextBeat on EPS
- FLEXFY2027 Q2 · October 28, 2026+11.3% EPS+11.6% move
- F-PCFY2026 Q3 · October 28, 2026+19.5% EPS— move
- RJFFY2026 Q4 · October 28, 2026+10.1% EPS-0.4% move
- NXTFY2027 Q2 · October 28, 2026+19.1% EPS+3.3% move
- CSLFY2026 Q3 · October 28, 2026+0.5% EPS-1.0% move
- BIIBFY2026 Q3 · October 28, 2026+31.7% EPS-3.4% move
Missed on EPS
- NOWFY2026 Q3 · October 28, 2026-2.0% EPS-3.0% move
- CMGFY2026 Q3 · October 28, 2026-7.1% EPS+2.7% move
- GOOGFY2026 Q3 · October 28, 2026-11.3% EPS+1.6% move
- MGMFY2026 Q3 · October 28, 2026-405.6% EPS-2.6% move
- CVNAFY2026 Q3 · October 28, 2026-11.6% EPS-0.3% move
- GOOGMFY2026 Q3 · October 28, 2026-29.6% EPS+1.0% move
Get the VTRS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-31T02:51:34.687298+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T02:51:34.684457+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-07-31. For educational purposes only; not investment advice.